Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Canakinumab in Adult-onset Still's Disease (AOSD)
2011-001027-20Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in adult-onset Still's disease (AOSD), sponsored by Charité – Universitätsmedizin Berlin. Started Dec 2011; status: terminated.
02
Drugs
canakinumab
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on 2011-001027-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001027-20.